Anders Vahlne

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Anders Vahlne, Professor Emeritus i Kliniskl Virologi, Karolinska Institute, före detta chefsöverläkare för det kliniskt virologiska laboratoriet vid Huddinge Universitetssjukhus. Nu medlem av Styrelesen och Exekutiv-kommittén för the Global Virus Network.
Anders Vahlne studerade till läkare vid Göteborgs Universitet, legitimerad läkare sedan 1973 och disputerade där i virologi 1978. 1982-83 tillbringade han som gästforskare vid
Scripps Clinic and Research Foundation i La Jolla, CA, med ett Fogarty Fellowship. Anders Vahlne var medlem av the President’s Advisory Board for the Irish National Virus Reference Laboratory vid University College Dublin från 2010 to 2021. Från 1972 till 1986 forskade Anders Vaahlne främst på herpes simplex virus neuropatogenesen. Därefter har hans forskning koncentrerats kring human retroviruses, särskilt HIV.

Forskningsbeskrivning

Herpes simplex virus neurobiology och pathogenes
HIV pathogenes
Virusdiagnostik

Undervisning

Klinisk virologi för medicinstudenter

Artiklar

Article: NATURE. 2022;611(7935):332-345
A multinational Delphi consensus to end the COVID-19 public health threat
Lazarus JV; Romero D; Kopka CJ; Karim SA; Abu-Raddad LJ; Almeida G; Baptista-Leite R; Barocas JA; Barreto ML; Bar-Yam Y; Bassat Q; Batista C; Bazilian M; Chiou S-T; del Rio C; Dore GJ; Gao GF; Gostin LO; Hellard M; Jimenez JL; Kang G; Lee N; Maticic M; McKee M; Nsanzimana S; Oliu-Barton M; Pradelski B; Pyzik O; Rabin K; Raina S; Rashid SF; Rathe M; Saenz R; Singh S; Trock-Hempler M; Villapol S; Yap P; Binagwaho A; Kamarulzaman A; El-Mohandes A
Article: ANTIVIRAL RESEARCH. 2019;163:140-148
2018 international meeting of the Global Virus Network
Brechot C; Bryant J; Endtz H; Garry RF; Griffin DE; Lewi SR; Mercer N; Osterhaus A; Picot V; Vahlne A; Verjans GMGM; Weaver S
Article: INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY. 2018;101:103-112
Identification and application of self-binding zipper-like sequences in SARS-CoV spike protein
Zhang SM; Liao Y; Neo TL; Lu Y; Liu DX; Vahlne A; Tam JP
Article: ANTIVIRAL RESEARCH. 2017;142:21-29
2016 International meeting of the Global Virus Network
Akkina R; Ellerbrok H; Hall W; Hasegawa H; Kawaguchi Y; Kleanthous H; McSweegan E; Mercer N; Romanowski V; Sawa H; Vahlne A
Article: PLOS ONE. 2015;10(7):e0134851
Membrane-Active Sequences within gp41 Membrane Proximal External Region (MPER) Modulate MPER-Containing Peptidyl Fusion Inhibitor Activity and the Biosynthesis of HIV-1 Structural Proteins
Zhang SM; Jejcic A; Tam JP; Vahlne A
Article: SCIENTIFIC REPORTS. 2014;4:7025
Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops
Moscoso CG; Xing L; Hui J; Hu J; Kalkhoran MB; Yenigun OM; Sun Y; Paavolainen L; Martin L; Vahlne A; Zambonelli C; Barnett SW; Srivastava IK; Cheng RH
Article: JOURNAL OF PHARMACY AND PHARMACOLOGY. 2014;66(10):1388-1393
Anti-human immunodeficiency virus type 1 agent alpha-hydroxy glycineamide enters the target cells via a mechanism of passive diffusion
Youssefi M; Vahlne A
Journal article: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999). 2014;65(&NA;):50
122 Peptide Inhibitors of HIV
Vahlne A
Article: AIDS. 2013;27(15):2355-2364
HIV-1 Tat protein induces viral internalization through Env-mediated interactions in dose-dependent manner
Poon S; Moscoso CG; Yenigun OM; Kolatkar PR; Cheng RH; Vahlne A
Journal article: AIDS. 2013;27(15):2345-2354
Putative role of Tat-Env interaction in HIV infection
Poon S; Moscoso CG; Xing L; Kan E; Sun Y; Kolatkar PR; Vahlne AG; Srivastava IK; Barnett SW; Cheng RH
Article: MOLECULAR THERAPY. 2013;21(9):1796-1805
Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C
Weiland O; Ahlen G; Diepolder H; Jung M-C; Levander S; Fons M; Mathiesen I; Sardesai NY; Vahlne A; Frelin L; Sallberg M
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2012;109(43):17639-17644
Human serum protein enhances HIV-1 replication and up-regulates the transcription factor AP-1
Perdomo MF; Hosia W; Jejcic A; Corthals GL; Vahlne A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2012;28(9):1052-1058
HIV Inhibition by CD4 and CCR5-Derived Glycopeptides
Perdomo MF; Sallberg M; Vahlne A
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2011;108(15):6091-6096
Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding
Moscoso CG; Sun Y; Poon S; Xing L; Kan E; Martin L; Green D; Lin F; Vahlne AG; Barnett S; Srivastava I; Cheng RH
Journal article: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999). 2011;56(Supplement 2):74
177 Peptide Linkers Between Natural Antibodies and HIV Target
Perdomo M; Sällberg M; Vahlne A
Article: RETROVIROLOGY. 2010;7:20
GPG-NH₂ acts via the metabolite αHGA to target HIV-1 Env to the ER-associated protein degradation pathway
Jejcic A; Hoglund S; Vahlne A
Article: JOURNAL OF VIROLOGY. 2009;83(19):10075-10084
Small Molecule Targets Env for Endoplasmic Reticulum-Associated Protein Degradation and Inhibits Human Immunodeficiency Virus Type 1 Propagation
Jejcic A; Daniels R; Goobar-Larsson L; Hebert DN; Vahlne A
Article: RETROVIROLOGY. 2009;6:40
A historical reflection on the discovery of human retroviruses
Vahlne A
Article: RETROVIROLOGY. 2009;6:34
Isolation and characterization of a small antiretroviral molecule affecting HIV-1 capsid morphology
Abdurahman S; Vegvari A; Levi M; Hoglund S; Hogberg M; Tong W; Romero I; Balzarini J; Vahlne A
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2008;52(10):3737-3744
Activity of the small modified amino acid α-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity
Abdurahman S; Vegvari A; Youssefi M; Levi M; Hoglund S; Andersson E; Horal P; Svennerholm B; Balzarini J; Vahlne A
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2008;105(34):12515-12520
Neutralization of HIV-1 by redirection of natural antibodies
Perdomo MF; Levi M; Sallberg M; Vahlne A
Article: RETROVIROLOGY. 2007;4:69
Characterization of the invariable residue 5I mutations of human immunodeficiency virus type I capsid protein on in vitro CA assembly and infectivity
Abdurahman S; Youssefi M; Hoglund S; Vahlne A
Article: RETROVIROLOGY. 2007;4:19
Mutation in the loop C-terminal to the cyclophilin A binding site of HIV-1 capsid protein disrupts proper virus assembly and infectivity
Abdurahman S; Hoglund S; Hoglund A; Vahlne A
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2005;49(3):1087-1092
Orally active antiviral tripeptide glycyl-prolyl-glycinamide is activated by CD26 (Dipeptidyl peptidase IV) before transport across the intestinal epithelium
Hubatsch I; Lazorova L; Vahlne A; Artursson P
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2005;49(1):40-44
Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide
Andersson E; Horal P; Jejcic A; Höglund S; Balzarini J; Vahlne A; Svennerholm B
Article: JOURNAL OF GENERAL VIROLOGY. 2004;85(Pt 10):2903-2913
Selected amino acid substitutions in the C-terminal region of human immunodeficiency virus type 1 capsid protein affect virus assembly and release
Abdurahman S; Höglund S; Goobar-Larsson L; Vahlne A
Article: INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY. 2004;36(9):1848-1859
Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH₂)
Balzarini J; Andersson E; Schols D; Proost P; Van Damme J; Svennerholm B; Horal P; Vahlne A
Article: ANTIVIRAL RESEARCH. 2004;61(2):119-124
No cross-resistance or selection of HIV-1 resistant mutants in vitro to the antiretroviral tripeptide glycyl-prolyl-glycine-amide
Andersson E; Horal P; Vahne A; Svennerholm B
Article: VIROLOGY. 2003;314(1):179-189
Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner
Naghavi MH; Nowak P; Andersson J; Sönnerborg A; Yang H; Tracey KJ; Vahlne A
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2002;46(11):3597-3605
Tripeptide interference with human immunodeficiency virus type 1 morphogenesis
Höglund S; Su J; Reneby SS; Végvári A; Hjertén S; Sintorn IM; Foster H; Wu YP; Nyström I; Vahlne A
Journal article: JOURNAL OF BIOMEDICAL SCIENCE. 2002;9(3):234-245
MCEF, the Newest Member of the AF4 Family of Transcription Factors Involved in Leukemia, Is a Positive Transcription Elongation Factor-b-Associated Protein
Estable MC; Naghavi MH; Kato H; Xiao H; Qin J; Vahlne A; Roeder RG
Article: JOURNAL OF BIOMEDICAL SCIENCE. 2002;9(3):234-245
MCEF, the newest member of the AF4 family of transcription factors involved in leukemia, is a positive transcription elongation factor-b-associated protein
Estable MC; Naghavi MH; Kato H; Xiao H; Qin J; Vahlne A; Roeder RG
Article: MOLECULAR THERAPY. 2001;3(4):531-535
Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1
Maijgren-Steffensson C; Sönnerborg A; Vahlne A; Britton S; Larsson S; Ährlund-Richter L
Article: JOURNAL OF GENERAL VIROLOGY. 2001;82(Pt 3):547-559
Upstream stimulating factor affects human immunodeficiency virus type 1 (HIV-1) long terminal repeat-directed transcription in a cell-specific manner, independently of the HIV-1 subtype and the core-negative regulatory element
Naghavi MH; Estable MC; Schwartz S; Roeder RG; Vahlne A
Article: JOURNAL OF HUMAN VIROLOGY. 2001;4(1):8-15
The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication
Su J; Naghavi MH; Jejcic A; Horal P; Furuta Y; Wu YP; Li SL; Hall WW; Goobar-Larsson L; Svennerholm B; Vahlne A
Article: JOURNAL OF HUMAN VIROLOGY. 2001;4(1):1-7
The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1
Su J; Andersson E; Horai P; Naghavi MH; Palm A; Wu YP; Eriksson K; Jansson M; Wigzell H; Svennerholm B; Vahlne A
Article: TRANSPLANTATION. 2000;69(8):1733-1736
Real-time monitoring of cytomegalovirus infections after stem cell transplantation using the TaqMan polymerase chain reaction assays
Yun ZB; Lewensohn-Fuchs I; Ljungman P; Vahlne A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2000;16(1):37-48
Deletion of the GPG motif in the HIV type 1 V3 loop does not abrogate infection in all cells
Su J; Palm A; Wu YP; Sandin S; Höglund S; Vahlne A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1999;15(14):1293-1303
Long terminal repeat promoter/enhancer activity of different subtypes of HIV type 1
Naghavi MH; Schwartz S; Sönnerborg A; Vahlne A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1999;15(7):609-617
No association of HIV type 1 long terminal repeat sequence pattern with long-term nonprogression and in vivo viral replication levels in European subjects
Visco-Comandini U; Yun ZB; Vahlne A; Sönnerborg A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1999;15(5):485-488
DNA sequence of the long terminal repeat of human immunodeficiency virus type I subtype A through G
Naghavi MH; Salminen MO; Sönnerborg A; Vahlne A
Article: JOURNAL OF HUMAN VIROLOGY. 1998;1(5):320-327
HIV-1 nef mutations and clinical long-term nonprogression. A molecular epidemiology study.
Visco-Comandini U; Yun Z; Paganelli R; Orlandi P; Salotti A; Johansson B; Vahlne A; Sönnerborg A
Article: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 1998;77(6):591-593
Increased serum concentrations of interleukin-2 receptor in the first trimester in women who later developed severe preeclampsia
Eneroth E; Remberger M; Vahlne A; Ringden O
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1998;14(3):241-248
Nonsynonymous mutations within the human immunodeficiency virus type 1 p17 gene are clustered to sequences binding to the host human leukocyte antigen class I molecules.
Birk M; Vahlne A; Sönnerborg A; Sällberg M
Article: JOURNAL OF VIROLOGICAL METHODS. 1997;69(1-2):171-180
Quantification of HIV-1 proviral DNA from peripheral blood mononuclear cells using a high throughput four-competitor competitive PCR
Comandini UV; Sönnerborg A; Vahlne A; Yun ZB
Article: CLINICAL AND VACCINE IMMUNOLOGY. 1997;4(5):627-629
Differences in humoral responses to the p24 antigen between Ethiopian and Swedish human immunodeficiency virus type 1-infected patients may suggest influences from a T-helper 2-like phenotype
Kebede T; Britton S; Fehniger T; Vahlne A; Sallberg M
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1996;12(18):1699-1702
Identification of cross-reactive antigenic target regions for HIV type 1-specific antibody-dependent cellular cytotoxicity
Broliden K; VonGegerfelt A; Persson C; Horal P; Svennerholm B; Wahren B; Bjorling E; Vahlne A
Article: AMERICAN JOURNAL OF HUMAN GENETICS. 1996;59(1):204-212
mtDNA variation indicates Mongolia may have been the source for the founding population for the New World
Merriwether DA; Hall WW; Vahlne A; Ferrell RE
Article: VIROLOGY. 1996;219(1):161-169
A novel ribozyme target site located in the HIV-1 Nef open reading frame
Larsson S; Hotchkiss G; Su J; Kebede T; Andang M; Nyholm T; Johansson B; Sonnerborg A; Vahlne A; Britton S; Ährlund-Richter L
Article: JOURNAL OF NEUROLOGY. 1996;243(3):214-224
Acyclovir treatment of relapsing-remitting multiple sclerosis - A randomized, placebo-controlled, double-blind study
Lycke J; Svennerholm B; Hjelmquist E; Frisen L; Badr G; Andersson M; Vahlne A; Andersen O
Article: JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 1996;11(1):10-19
Characterization of an antigen shared by human thymic epithelium and human T cell leukemia virus p19 gag protein
Palker TJ; Singer KH; Vahlne A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1995;11(5):637-645
EXTRAORDINARY HIGH-RATE OF HTLV TYPE-II SEROPOSITIVITY IN INTRAVENOUS DRUG-ABUSERS IN SOUTH-VIETNAM
FUKUSHIMA Y; TAKAHASHI H; HALL WW; NAKASONE T; NAKATA S; SONG P; DUC DD; HIEN B; QUANG NX; TRINH TN; NISHIOKA K; KITAMURA K; KOMURO K; VAHLNE A; HONDA M
Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1994;91(26):12559-12563
INFECTION OF VAGINAL AND COLONIC EPITHELIAL-CELLS BY THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IS NEUTRALIZED BY ANTIBODIES RAISED AGAINST CONSERVED EPITOPES IN THE ENVELOPE GLYCOPROTEIN GP120
FURUTA Y; ERIKSSON K; SVENNERHOLM B; FREDMAN P; HORAL P; JEANSSON S; VAHLNE A; HOLMGREN J; CZERKINSKY C
Journal article: AIDS. 1994;8(7):971-976
PREVALENCE OF HIV-1 INFECTION IN RURAL, SEMIURBAN AND URBAN VILLAGES IN SOUTHWEST TANZANIA - ESTIMATES FROM A BLOOD-DONOR STUDY
SODERBERG S; TEMIHANGO W; KADETE C; EKSTEDT B; MASAWE A; VAHLNE A; HORAL P
Journal article: EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES. 1990;9(10):751-757
NEUROVIRULENCE OF HERPES-SIMPLEX VIRUS TYPE-1 AND TYPE-2 ISOLATES IN DISEASES OF THE CENTRAL-NERVOUS-SYSTEM
BERGSTROM T; ALESTIG K; SVENNERHOLM B; HORAL P; SKOLDENBERG B; VAHLNE A
Journal article: ANNALS OF OTOLOGY, RHINOLOGY AND LARYNGOLOGY. 1988;97(5):554-558
INVASION OF CRANIAL NERVES AND BRAIN-STEM BY HERPES-SIMPLEX VIRUS INOCULATED INTO THE MOUSE TONGUE
THOMANDER L; ALDSKOGIUS H; KRISTENSSON K; VAHLNE A; THOMAS E
Journal article: JOURNAL OF GENERAL VIROLOGY. 1986;67:2023-2028
NEURITIC TRANSPORT OF HERPES-SIMPLEX VIRUS IN RAT SENSORY NEURONS INVITRO - EFFECTS OF SUBSTANCES INTERACTING WITH MICROTUBULAR FUNCTION AND AXONAL FLOW [NOCODAZOLE, TAXOL AND ERYTHRO-9-3-(2-HYDROXYNONYL)ADENINE]
KRISTENSSON K; LYCKE E; ROYTTA M; SVENNERHOLM B; VAHLNE A
Journal article: JOURNAL OF GENERAL VIROLOGY. 1984;65(JAN):55-64
UPTAKE AND TRANSPORT OF HERPES-SIMPLEX VIRUS IN NEURITES OF RAT DORSAL ROOT-GANGLIA CELLS IN CULTURE
LYCKE E; KRISTENSSON K; SVENNERHOLM B; VAHLNE A; ZIEGLER R
Journal article: JOURNAL OF THE NEUROLOGICAL SCIENCES. 1982;53(2):205-216
VIRUS-INDUCED DEMYELINATION IN HERPES-SIMPLEX VIRUS-INFECTED MICE
KRISTENSSON K; SVENNERHOLM B; VAHLNE A; NILHEDEN E; PERSSON L; LYCKE E
Journal article: JOURNAL OF THE NEUROLOGICAL SCIENCES. 1979;43(2):253-263
Latent herpes simplex virus trigeminal ganglionic infection in mice and demyelination in the central nervous system.
Kristensson K; Svennerholm B; Persson L; Vahlne A; Lycke E
Journal article: JOURNAL OF THE NEUROLOGICAL SCIENCES. 1978;35(2-3):331-340
Neural spread of herpes simplex virus types 1 and 2 in mice after corneal or subcutaneous (footpad) inoculation.
Kristensson K; Vahlne A; Persson LA; Lycke E
Visa fler

Alla övriga publikationer

Review: ISCIENCE. 2023;26(6):106935
Biological mechanisms underpinning the development of long COVID
Perumal R; Shunmugam L; Naidoo K; Wilkins D; Garzino-Demo A; Brechot C; Vahlne A; Nikolich J
Review: VACCINE. 2023;41(20):3171-3177
Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategies
Roper RL; Garzino-Demo A; Del Rio C; Brechot C; Gallo R; Hall W; Esparza J; Reitz M; Schinazi RF; Parrington M; Tartaglia J; Koopmansm M; Osorio J; Nitsche A; Huan TB; LeDuc J; Gessain A; Weaver S; Mahalingam S; Abimiku A; Vahlne A; Segales J; Wangx L; Isaacs SN; Osterhaus A; Scheuermann RH; McFadden G
Review: FRONTIERS IN IMMUNOLOGY. 2023;14:1117464
Long COVID: a review and proposed visualization of the complexity of long COVID
Perumal R; Shunmugam L; Naidoo K; Abdool Karim SSS; Wilkins D; Garzino-Demo A; Brechot C; Parthasarathy S; Vahlne A; Nikolich JZ
Letter: THE LANCET. 2020;396(10248):e15
COVID-19-a very visible pandemic
King C; Einhorn L; Brusselaers N; Carlsson M; Einhorn S; Elgh F; Frisen J; Gustafsson A; Hanson S; Hanson C; Hedner T; Isaksson O; Jansson A; Lundkvist A; Lotvall J; Lundback B; Olsen B; Soederberg-Naucler C; Wahlin A; Steineck G; Vahlne A
Review: ANTIVIRAL RESEARCH. 2019;172:104645
2019 meeting of the global virus network
Akkina R; Garry R; Brechot C; Ellerbrok H; Hasegawa H; Menendez-Arias L; Mercer N; Neyts J; Romanowski V; Segales J; Vahlne A
Editorial comment: ACTA PAEDIATRICA, INTERNATIONAL JOURNAL OF PAEDIATRICS. 2016;105(7):728-729
How Zika virus made the transition from being a virtually unknown virus to a high-profile public health threat
Vahlne A
Letter: AIDS. 2013;27(10):1680-1682
Human serum increases CD4 recycling to plasma membranes of in-vitro cultured cells
Perdomo MF; Vahlne A
Meeting abstract: RETROVIROLOGY. 2005;2:s94
AlphaHGA;: A new antiviral substance against HIV affecting capsid assembly
Vahlne A; Abdurahman S; Levi M; Andersson E; Svennerholm B; Horal P; Jejcic A; Hoglund S; Vegvaris A; Hogberg M; Balzarini J
Meeting abstract: RETROVIROLOGY. 2005;2:p80
Redirecting the specificity of naturally occurring antibodies using gal-alpha1, 3-gal coupled to HIV recognizing peptides
Perdomo M; Levi M; Sallberg M; Vahlne A
Letter: AIDS. 2000;14(1):91-92
Coreceptor usage of HIV-1 after deletion of Gly317-Pro318-Gly319 motif in the gp120 V3 loop
Su J; Vahlne A
Conference publication: AIDS. 2000;14:S17-S18
An initial safety and efficacy clinical trial of GPG-NH₂, a tripeptide with a new antiretroviral made of action
Pehrson PO; Sönnerborg A; Vahlne A; Spira J
Other: JOURNAL OF INFECTIOUS DISEASES. 1995;172(5):1343-1347
EMERGENCE OF PRECORE TAG MUTATION DURING HEPATITIS-B-E SEROCONVERSION AND ITS DEPENDENCE ON PREGENOMIC BASE-PAIRING BETWEEN NUCLEOTIDE-1858 AND NUCLEOTIDE-1896
LINDH M; FURUTA Y; VAHLNE A; NORKRANS G; HORAL P
Conference publication: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY. 1985;9(3):310-311
HERPES-SIMPLEX VIRUS-INFECTION OF NEURONAL CELLS-INVITRO
LYCKE E; KRISTENSSON K; SVENNERHOLM B; VAHLNE A; ZIEGLER R

Anställningar

Professor Emeritus/Emerita, Laboratoriemedicin, Karolinska Institutet, 2023-2026

Examina och utbildning

Docent, klinisk virologi, Göteborgs Universitet, 1980

Om mig

Forskningsbeskrivning

Undervisning

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI